Non-Small Cell Lung Cancer
Conditions
Keywords
Non-Small Cell Lung Cancer, Multiomics analysis, Tumor immune microenvironment, Radiomics, Pathological response, Immune-related adverse event, Nursing prehabilitation
Brief summary
The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing original techniques and clinical applications.
Detailed description
Lung cancer remains the leading cause of cancer-related mortality in China and globally, imposing a substantial disease burden on society. Although comprehensive treatment strategies centered on surgery have improved patient outcomes, and perioperative immunotherapy-particularly immune checkpoint inhibitors-has profoundly reshaped the therapeutic landscape, significant knowledge gaps and critical challenges persist in this field. These challenges include uncertain beneficiary populations, poorly understood immune mechanisms, inaccurate efficacy prediction, difficult determination of resection margins, controversial efficacy assessment, and lack of effective early warning for adverse reactions. This study will systematically identify biomarkers for early diagnosis and recurrence monitoring through multi-omic analysis of peripheral blood immune cell subsets and non-invasive liquid biopsies; investigate the tumor immune microenvironment's role in immunotherapy response mechanisms and predict treatment efficacy via multi-omic studies of tissue specimens; develop novel AI- and radiomics-assisted pathological assessment systems and prognostic prediction models; implement perioperative symptom assessment for timely identification of immune-related adverse events (irAEs) while conducting prehabilitation training for perioperative nursing care.
Interventions
None listed
Sponsors
Beijing Municipal Health Commission
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old; 2. NSCLC patients underwent radical surgical resection; 3. Adequate clinical-pathologic data, imaging data and follow-up data obtainable for multi-omics analysis; 4. Scheduled for or currently receiving neoadjuvant/perioperative immunotherapy.
Exclusion criteria
1. Histology of other malignant tumors, including concurrent malignant tumors of other organ systems; 2. Unresectable advanced disease (Stage IV) or locally advanced unresectable (Stage IIIC); 3. Pregnancy or lactation; 4. Insufficient sample quality; 5. Severe organ dysfunction (e.g. cardiac or renal insufficiency); 6. Other judgments by the Investigator that the patient should not participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological Complete Response (pCR) | At surgery (typically 3-6 months post-treatment initiation) | Pathologic Complete Response (pCR) is defined as the absence of residual tumor in both the primary lung tumor site and all sampled regional lymph nodes after neoadjuvant immunotherapy, confirmed through systematic pathological examination of the surgical specimen. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | After two cycles or four cycles of neoadjuvant therapy (each cycle is 21 days). | ORR is defined as the proportion of patients achieving either a complete response (CR; disappearance of all target lesions) or partial response (PR; ≥30% reduction in the sum of target lesion diameters) during or after neoadjuvant immunotherapy, as assessed by serial imaging (CT/PET-CT) using iRECIST criteria. |
| Recurrence-free Survival (RFS) | Through study completion, an average of 2 years | Time from randomization to disease recurrence or death from any cause. |
| Overall Survival (OS) | Through study completion, an average of 2 years | Time from randomization to death from any cause. |
| Major Pathological Response (MPR) | At surgery (typically 3-6 months post-treatment initiation) | Major Pathologic Response (MPR) is defined as the presence of ≤10% residual viable tumor cells in both the primary lung tumor site and sampled regional lymph nodes after neoadjuvant immunotherapy, confirmed through systematic pathological examination of the surgical specimen. |
| Symptom Severity Score | Preoperative (T1: 2-4 weeks pre-surgery), postoperative (e.g., T3: 12-24 hours post-surgery, T5: 30 days post-surgery), and up to 90 days post-surgery. | Assessment of perioperative symptom burden (e.g., pain, fatigue) using validated scales like the MDASI-C (M. D. Anderson Symptom Inventory) for lung cancer patients. |
| Immune-Related Adverse Event (irAE) Incidence | Periprocedural and up to 6 months post-treatment. | Frequency and severity of adverse events (e.g., rash, colitis) related to immunotherapy, graded using standardized criteria like CTCAE (Common Terminology Criteria for Adverse Events). |
| Changes in PD-L1 expression (TPS) and TIL subpopulations (CD8+/FOXP3+ ratios, et al) before and after neoadjuvant immunotherapy | Periprocedural. | PD-L1 expression (22C3 pharmDx assay; TPS ≥1% cutoff), multiplex immunofluorescence (CD8: clone C8/144B; FOXP3: clone 236A/E7) and multomoics analyses were performed on paired pre-/post-NAD biopsies. |
| MRD (minimal residual disease) dynamics after neoadjuvant immunotherapy | Periprocedural and every three to six months post-treatment (up to three years) | Postoperative dynamics of ctDNA-based MRD and timely detection of recurrence or metastasis in lung cancer patients receiving neoadjuvant immunotherapy. |
Contacts
Primary ContactHao Li, MD
Backup ContactTianxiao Han, MD
Outcome results
None listed